|
Market Closed -
Nasdaq
16:00:00 2026-10-19 EDT
|
5-day change | 1st Jan Change | ||
| 8.330 USD | -2.57% |
|
-8.21% | -7.06% |
Company Valuation: Xilio Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 437.3 | 73.73 | 15.14 | 41.98 | 33.61 | 54.81 | - | - |
| Change | - | -83.14% | -79.46% | 177.26% | -19.94% | 63.08% | - | - |
| Enterprise Value (EV) | 249 | -36.83 | -26.25 | -13.31 | 33.61 | 54.81 | 54.81 | 54.81 |
| Change | - | -114.79% | 28.73% | 49.29% | 352.5% | 63.08% | 0% | 0% |
| P/E | -1.18x | -0.84x | -0.2x | -0.88x | -2.14x | -3.22x | -3.74x | -2.61x |
| PBR | 2.37x | 0.7x | 0.41x | 2.48x | - | - | - | - |
| PEG | - | 0x | 0x | 0x | 0x | 0.1x | 0.3x | -0.1x |
| Capitalization / Revenue | - | - | - | 6.62x | 0.77x | 1.36x | 2.07x | 8.59x |
| EV / Revenue | - | - | - | -0x | 0x | 1.36x | 2.07x | 8.59x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -189.3 | -45.08 | -38.92 | -15.26 | -4.19 | -2.59 | -2.23 | -3.19 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 6.344 | 43.77 | 40.33 | 26.53 | 6.38 |
| EBITDA | -73.54 | -87.3 | -77.23 | -58.94 | - | - | - | - |
| EBIT | -75.04 | -89.15 | -79.13 | -60.58 | - | - | - | - |
| Net income 1 | -75.8 | -88.22 | -76.4 | -58.24 | -35.04 | -48.7 | -45.4 | -78.4 |
| Net Debt | -188.3 | -110.6 | -41.39 | -55.29 | - | - | - | - |
| Reference price 2 | 224.000 | 37.660 | 7.700 | 13.370 | 8.963 | 8.330 | 8.330 | 8.330 |
| Nbr of stocks (in thousands) | 1,952 | 1,958 | 1,966 | 3,140 | 3,750 | 6,580 | - | - |
| Announcement Date | 3/1/22 | 3/2/23 | 4/1/24 | 3/11/25 | 3/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.3x | - | - | - | 56.26M | |
| 18.77x | 6.69x | 13.41x | 1.58% | 65B | |
| 35.3x | 6.27x | 18.74x | 0.92% | 51.2B | |
| 27.56x | 7.53x | 23.83x | 0.05% | 51.19B | |
| 34.01x | 3.32x | 14.33x | -.--% | 43.93B | |
| 48.9x | 5.59x | 30.73x | -.--% | 41.96B | |
| -18.47x | 189.62x | -19.51x | -.--% | 38.14B | |
| 28.97x | 8.21x | 21.25x | 0.37% | 33.24B | |
| 29.19x | 6.17x | 16.01x | -.--% | 25.2B | |
| 30.74x | 5.69x | 19.09x | -.--% | 22.5B | |
| Average | 23.17x | 26.57x | 15.32x | 0.32% | 37.24B | |
| Weighted average by Cap. | 25.96x | 25.01x | 15.48x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- XLO Stock
- Valuation Xilio Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
